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Controlling the cost of prescription drugs is integral to improving health outcomes, and 
patient access and adherence to treatment. While prescription drugs can often provide essential 
therapeutic benefit, previous studies have suggested that inappropriate prescription drug use is a 
principal cause of adverse drug events as well as abuse and diversion of drugs. Thus, balancing 
the benefits and harms to promote appropriate prescription drug use is an essential component of 
healthcare delivery in the United States. There are multiple ways appropriate prescription drug 
use is promoted. Black-box warnings and drug labeling controlled by the FDA as well as 
guidelines released by the CDC, such as the 2013 guidelines released during the opioid epidemic, 
aim to promote appropriate prescription at a population level. At a patient-level, drug formularies 
have multiple strategies in place to promote safe and cost-effective prescribing of individual 
medications. 
The Center for Medicare & Medicaid Services (CMS) makes use of prescription drug 
formularies that are used for the coverage of around 17% of the US population. These 
formularies have uniformly adopted utilization management strategies, such as quantity limits, 
prior authorization, and step therapy, in order to promote safe, evidence-based and cost-effective 
prescribing. These strategies are in place to impact drug prescription rates as well as to 
incentivize use of biological or therapeutically interchangeable generics over brand-name drugs. 
Thus far, the implementation of utilization management strategies for commonly prescribed 
drugs has not been thoroughly studied.  
This study presents three main analyses conducted and published in the peer reviewed 
literature during my time in medical school. The first characterized the change in opioid 
prescription versus non-opioid analgesics in both the outpatient and emergency room setting in 
3 
 
the context of the 2013 CDC guidelines encouraging prescription on non-opioid analgesic 
alternatives. We found that overall rates of pain medication prescribing were high and that opioid 
pain medication prescription increased in the outpatient setting only, whereas non-opioid pain 
medication prescribing increased in both the outpatient and ED settings, an area that has not been 
previously reported or well-investigated. 
The second study characterized how Medicare formulary restrictions were applied to 
opioid “potentiators”, which are commonly used in conjunction with opioids and increase 
patients’ risk of adverse events. We found that from 2013-2017, Medicare prescription drug plan 
formularies had relatively unchanged rates of benzodiazepine, non-benzodiazepine sedative-
hypnotic, and gabapentinoid coverage with small increases in use of quantity limits, and that 
more than a quarter of formularies provided unrestrictive coverage of these potentially unsafe 
opioid potentiators in 2017. 
The third and final study herein presents a more global analysis of whether Medicare 
used formulary restrictions to promote prescription of therapeutically interchangeable generics 
over the top 100-grossing brand-name drugs in light of the 2020 CMS plans for an indication-
based formulary design. We showed that a substantial portion of CMS formularies provided 
similarly restrictive coverage of brand-name drugs and their therapeutically interchangeable 
generics, including the same tier placement or utilization management, thereby missing 
opportunities to incentivize prescribing of less costly generics. 
Overall, the results of this comprehensive study on safe and cost-effective drug 
prescription showed that while current formulary design includes opportunities to reduce costly 
and potentially unsafe prescribing, the impact of these tools is sub-optimal. These results 
highlight the need for both physician and patient education on the utility of the formulary 
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restriction strategies. On a larger scale, it suggests that these strategies alone may not be 
sufficient to reduce over-prescription of potentially unsafe drugs like opioid potentiators, or to 
incentivize prescription of cost-saving generics over brand-name drugs.  The Center for 
Medicare & Medicaid Services (CMS) has proposed an indication-based formulary design 
starting in 2020, allowing Medicare Advantage and Part D prescription drug plans to cover drugs 
only for select indications, which could increase formulary negotiating power and secure more 
competitive pricing. This might be the change needed in order to ensure continued patient access 
to affordable and safe prescription drugs. 
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1.1 Safe and Cost-Effective Prescribing 
Access to safe, cost-effective prescription drugs is integral to increasing patient 
adherence, improving patient health outcomes and ultimately decreasing all-cause medical costs 
1, 2. Previous studies have suggested that inappropriate prescription drug use is a principal cause 
of adverse drug events (ADEs), which in turn can lead to additional physician visits, 
hospitalizations, injury, deterioration of body functioning, and death 3. Inappropriate prescription 
drug use on the patient side can also lead to addiction, diversion and overdose deaths 4. Thus, 
balancing harms and benefits of prescription drug use by incentivizing appropriate prescription is 
paramount in ensuring positive health outcomes across a broad range of patient populations. 
 At a population level, safe drug prescribing is controlled by the Food and Drug 
administration (FDA) through labeling and black box warnings, as well as through CDC 
guidelines 5. Cost-effective drug prescription can be promoted in part through the incentivization 
of generic drugs over brand-name equivalents 6. At a patient level, there have been various 
strategies adopted: requiring communication between pharmacist and physician at time of 
dispensation, requiring prescription drug monitoring programs to be in place for high-risk 
medications, and utilization management strategies incorporated within drug formulary policies 
4, 7, 8.  
Utilization management strategies, in theory, act to control costs of expensive branded 
drugs as well as prevent over-prescription of potentially unsafe drugs. These strategies include 
tiering of formularies (drugs are divided into “tiers,” with the first tier typically representing 
generics at the lowest level of patient cost-sharing, and a higher tier requiring higher patient cost-
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sharing), prior authorization (requiring physicians to obtain approval from the health plan before 
prescription for coverage) and quantity limits (limiting the amount of drug a patient can receive 
over a given amount of time) 9. A case study of opioid coverage among a private insurer showed 
that implementing these restriction strategies lead to a 15% decrease in opioid prescribing, 
suggesting that these methods can be used for their intended effect 10. Another study on 
rosiglitazone, which has a black box warning on increased risk of myocardial ischemia, showed 
that there was reduced rosiglitazone prescribing associated with Medicaid plans that 
implemented formulary restrictions compared with plans without formulary restrictions, although 
overall, these restrictions were underutilized 11. 
 
1.2 Controlling Prescription with Restriction Strategies – Effective or Not? 
Studying the impact of formulary management on drug prescription is a new and emerging field, 
still understudied. Previous studies have often focused on a specific therapeutic drug class, from 
anti-thrombotics to antihyperglycemic agents, or specific FDA labeling, such as black box 
warnings. By and large, the results of these studies show a) that many drugs of concern remain 
relatively unrestricted, b) that the restrictions had little impact on how providers managed 
treatment regimens, and c) that for many drugs, brand-name and generics are treated very 
similarly. All of this taken together suggests sub-optimal utilization or relative ineffectiveness of 
the formulary management strategies despite pilot studies. Furthermore, even in cases where 
formulary restrictions were shown to decrease prescription of targeted drugs, there was less 
consensus on whether this actually affected patient costs and health outcomes 12. Table 1 shows 
results from these past studies.   
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Table 1. Past Studies Examining Impact of Formulary Management Strategies on Drug 
Prescription 
Author Title Year Therapeutic 
Area Studied 
Main Finding 
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1.3 Opioid Prescriptions – A Changing Landscape 
The United States is currently facing an opioid epidemic, which began in the mid-1990s 
with increased pharmaceutical marketing, as well as promotion by both hospital accrediting 
bodies and official medical societies 13. Emergency department (ED) visits for opioid overdoses 
rose 30% across the country from July 2016 through September 2017 14, 15. Opioid-related deaths 
were five times higher in 2016 than 1999 15. In response, the Centers for Disease Control and 
Prevention (CDC) issued guidelines in 2013 encouraging the replacement of opioid medications 
with non-opioid alternatives to treat chronic pain 16. Despite such efforts, opioid-related harms 
have been rising nationwide. 
While a study of nationwide opioid prescriptions from 2002-2013 suggested that opioid 
prescriptions began to decline prior to the 2013 CDC guideline announcement 17, the response to 
these guidelines has not been very well studied.  Samuels et al. demonstrated that prescription of 
opioids through CMS formularies remained relatively unrestricted, especially at high doses and 
for the particular medications that have higher rates of overdose deaths 18. Partly as a result of 
these findings combined with the 2013 CDC guidelines, Medicare recently proposed formulary 
changes to restrict opioid availability based on maximum daily dosage and initial fill quantity.19 
In order to fully understand the impact of these findings and characterize the relationship 
between formulary restriction and nationwide prescription rates, it was necessary to examine the 
nationwide changes in opioid prescribing rates versus non-opioid analgesic prescriptions after 
the 2013 CDC guidelines were announced, especially in an outpatient setting where formulary 
restrictions are quite relevant to patient access to medication. The objective of the first study was 
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thus to investigate and compare current prescribing rates of opioid medications, including 
fentanyl, and of non-opioid medications in the outpatient and emergency department settings 
using a nationally-representative sample. 
  
1.4 Opioid potentiators – a new epidemic 
A currently under-recognized but important concern concurrent to the opioid epidemic is 
the over-prescription of “opioid potentiator” drug classes:  benzodiazepines, non-benzodiazepine 
sedative-hypnotics, and gabapentinoids.20, 21 These drugs have risks when used on their own; 
benzodiazepines, in particular, have the second highest overdose death rate after opioids.22 In 
addition, they increase the risk of an adverse event when taken with opioids. Figure 1, taken 
from the CDC, graphically shows the role of opioid and opioid potentiator co-prescription within 
the umbrella of the opioid epidemic. 
Figure 1. Opioid Overdose Deaths Involving Benzodiazepines (source: CDC, 




Unfortunately, it appears there has been little effort to decrease prescribing of these 
potentially dangerous drugs. Between 1996 and 2013, the number of adults who filled a 
benzodiazepine prescription increased by 67%, and the quantity of benzodiazepines obtained 
more than tripled .23 While the MMA excluded benzodiazepines in 2006 because of multiple 
reported adverse effects in the elderly, they eventually gained coverage in 2014 under Part D for 
any medically accepted indication 24, 25. A recent study indicates that subsequent to a 2016 CDC 
guideline release recommending avoidance of concurrent opioid and benzodiazepines use, the 
intensity of benzodiazepine prescription has not reduced and the rate of co-prescribing only 
decreased by a small amount 26. 
Overuse of the non-benzodiazepine sedative hypnotics is associated with increased 
mortality and adverse outcomes such as fractures, falls and cognitive impairment.27 Nonetheless, 
more than 50% of patients within hospitals may receive these medications, which are sometimes 
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continued after discharge.28 Gabapentinoids have also seen a surge in prescribing in recent years 
for a broad range of pain diagnoses.  In a recent study of a Medicaid managed care population, 
95% of gabapentin prescribing was for off-label indications.29  
Despite evidence that these medications are being increasingly prescribed and can have 
devastating effects, especially in combination with opioids, examination of how Medicare 
controls coverage of opioid potentiators had not been previously characterized. The aim of the 
second study was to characterize Medicare formulary coverage and restriction of 
benzodiazepines, non-benzodiazepine sedative-hypnotics, and gabapentinoids from 2013-2017. 
1.5 Therapeutic Exchange – Incentivizing Generic over Brand Drug Prescription to Reduce 
Patient Costs 
U.S. prescription drug sales, excluding physician administered drugs, accounted for 
nearly 10% of total healthcare spending in 2017 30. Given that generic drugs are generally less 
expensive than brand-name drugs for patients, and that these lower out-of-pocket costs can 
improve patient adherence, preferential prescription of generic drugs over brand-name is one 
important target in improving health outcomes 1. While generic substitution is critical to 
curtailing prescription drug spending, a previous study has shown that 72% of current 
formularies favor pricier, branded drugs over bioequivalent generics in at least one therapeutic 
area 31. 
It is apparent that the incentivization of generic prescribing through formulary restriction 
is not uniform across drug classes. The issue is further complicated in that not all brand-name 
drugs have an approved bioequivalent generic. However, for many drugs, therapeutically 
interchangeable generics are available, offering potential cost savings if substituted. Therapeutic 
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interchangeables are drugs within the same class, with similar clinical effect and safety profile, 
but with a different chemical composition of the drug of interest 32- for brand-name drugs 
without an approved generic bioequivalent, a TE can usually be substituted. In fact, one study 
estimated that between 2010 and 2012, $73 billion could have been saved by TE substitution for 
the most commonly prescribed medication classes 33. 
The Center for Medicare & Medicaid Services (CMS) has proposed an indication-based 
formulary design starting in 2020 34, allowing Medicare Advantage and Part D prescription drug 
plans to cover brand-name drugs only for select indications. This could potentially increase 
formulary negotiating power and secure more competitive pricing. The indication-based 
formulary design also defines a role of the therapeutic interchangeable, as the formulary must 
ensure coverage with a therapeutic interchangeable of any indication not covered by the 
corresponding brand-name drug. With the new formulary design in the horizon, the third study 
aimed to understand if and how 2016 Medicare prescription drug plan formularies incentivize 
selection of brand-name drugs without bioequivalent generics compared to their corresponding 
therapeutically interchangeable generic drugs through tier placement and utilization management 
strategies. 
2. STATEMENT OF PURPOSE 
The purpose of this thesis is to describe three published studies that systematically 
characterize the relationship between CMS formulary regulations and a) safe and evidence-based 
prescribing, using opioids and opioid potentiators as a case study, b) cost-effective prescribing 
using therapeutic exchanges across a broad, nationally representative drug sample.  
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Study 1: U.S. Prescribing Trends of Opioids, Fentanyl and Other Pain Medications in 
Outpatient and Emergency Department Visits from 2006-2015: 
Examination of national opioid versus non-opioid analgesic prescription rates before and after 
release of CDC guidelines encouraging prescription of non-opioid analgesics. 
Study 2: Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 
2013-2017: 
Characterization of CMS formulary coverage, including utilization management strategies, of 
opioid potentiators such as benzodiazepines, non-benzodiazepine sedative hypnotics and 
gabapentinoids. 
Study 3: Medicare Formulary Coverage of Brand-Name Drugs with Available FDA-
Approved Therapeutically Interchangeable Generics 
Characterization of how 2016 Medicare prescription drug plan formularies incentivize selection 
of top 100-grossing brand-name drugs without bioequivalent generics compared to their 
corresponding therapeutically interchangeable generic drugs through tier placement and 
utilization management strategies. 
Medicare files provide a broad and impactful perspective on key components of health 
care in the United States. Medicare is the largest national insurer, accounting for 29% of United 
States’ total prescription drug spending and covering 17% of the nation’s patient population. 
Thus, it has a strong impact on nationwide drug demand. In fact, Medicare coverage policies 
often drive private insurance coverage decisions 9. Finally, Medicare primarily provides 
prescription drug coverage to an older adult population (>65 yo) vulnerable because of the need 
for more medications combined with limited or fixed incomes 3. Therefore, findings on the 
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impact of Medicare formulary restrictions on prescription drug policy are fairly nationally 
representative and especially impactful regarding safe and affordable access to prescription 
drugs. 
3. STUDY 1 – METHODS AND RESULTS 
3.1 U.S. Prescribing Trends of Opioids, Fentanyl and Other Pain Medications in 
Outpatient and Emergency Department Visits from 2006-2015 
Data Source 
We used 2006-2015 data from the National Ambulatory Medical Care Survey (NAMCS) 
and National Hospital Ambulatory Medical Care Survey (NHAMCS), which provide nationally 
representative samples of office-based outpatient visits and emergency department visits, 
respectively (https://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm). NAMCS and NHAMCS 
both sample non-federally employed physicians who are primarily engaged in direct patient care 
– the sampling design utilizes a stratified two-stage sample, with physicians selected in the first 
stage and visits in the second stage. The data provide an analytic base that serves as an important 
tracking tool on ambulatory and emergency care utilization regarding national trends, medication 
use, and practice patterns in the US. Samples included 390,538 visits in NAMCS and 305,570 
visits in NHAMCS.  
Drug Sample 
To characterize pain medication prescribing, we examined the first eight medications 
listed for all outpatient and ED visits, ensuring consistency across all survey years. We 
constructed three indicator variables using generic names of medications: fentanyl products (i.e., 
fentanyl and droperidol-fentanyl), all opioid products other than fentanyl (including analogues), 
and all other non-opioid pain medications. Opioid products other than fentanyl consisted of the 
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following medications: codeine, meperidine, methadone, alfentanil, hydromorphone, morphine, 
oxycodone, pentazocine, propoxyphene, sufentanil, opium, levorphanol, oxymorphone, 
butorphanol, nalbuphine, buprenorphine, hydrocodone, dihydrocodeine, remifentanil, tapentadol, 
and their combined products. Other non-opioid pain medications are nonsteroidal anti-
inflammatory drugs (NSAIDs), non-analgesics, and other drugs (i.e., acetaminophen, aspirin, 
diclofenac, ibuprofen, indomethacin, ketoprofen, ketorolac, naproxen, phenylbutazone, 
piroxicam, tolmetin, tramadol, gabapentin, and pregabalin).  
Demographics 
We included a number of patient demographic and clinical covariates provided during 
visits. Demographic variables included: age (<19, 19-44, 45-64, or ≥65), gender, race/ethnicity 
(non-Hispanic white, non-Hispanic black, Hispanic, or other), primary source of payment 
(private, Medicare, Medicaid, or other). Medicare is a federal program that provides health 
coverage for US adults over the age of 65, and Medicaid is a state and federal program that 
provides health coverage for low-income individuals and families. Clinical variables included 
visit diagnosis and physician specialty. Both NAMCS and NHAMCS collect up to three visit 
diagnoses for each sampled visit using the International Classification of Diseases, 9th edition, 
Clinical Modification (ICD-9-CM) diagnostic codes. We categorized visit diagnosis into three 
groups: cancer-related pain diagnoses, non-cancer related pain diagnoses, and no pain-related 
diagnosis. For physician specialty, we distinguished between generalists (i.e., general/family 
practice, internal medicine, pediatrics, and obstetrics and gynecology) vs. other in NAMCS. In 
NHAMCS, we distinguished clinical specialty by clinical degree (i.e., MD vs. other). We also 
reported number of visits in the past 12 months (0, 1-2, 3-5, or ≥6), number of chronic conditions 




We determined the proportion of visits for which any pain medication was prescribed and 
examined associations with selected characteristics (e.g., age, sex, race/ethnicity, clinical 
comorbidities, concomitant medication use, and physician specialty), using Bonferroni-adjusted 
bivariate analyses. Next, we determined the proportion of visits for which any pain medication 
was prescribed across survey years, overall and for each pain medication class, also stratifying 
overall analyses by selected patient and visit characteristics. We used Chi-Square analysis to 
compare rates in 2006-2007 and 2014-2015. All analyses were conducted using Stata MP/6-Core 
version 15.1 (College Station, TX), accounting for the complex survey design and sampling 
weights.  
 
3.2 U.S. Prescribing Trends of Opioids, Fentanyl and Other Pain Medications in 
Outpatient and Emergency Department Visits from 2006-2015 
Selected characteristics of the study subjects 
Between 2006 and 2015, 66,987 (17.4%) of 390,538 office-based outpatient visits 
(nationally-representative of 961 million visits) and 134,953 (45.0%) of 305,570 ED visits 
(nationally-representative of 130 million visits) listed a pain medication prescription (Table 2). 
56.3% of office-based outpatient visits were to primary care physicians, and of these visits, 
18.3% involved a prescription for a pain medication. Among office-based outpatient visits, pain 
medication prescription was highest among patients aged 45-64, non-Hispanic Black patients, 
patients with Medicare coverage, patients receiving care from primary care physicians, and 
patients receiving care for a pain-related diagnosis (all p-values < 0.001). Among ED visits, pain 
medication prescription was highest among patients aged 19-44, males, Hispanic patients, 
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patients with private insurance, patients receiving care from MDs, and patients receiving care for 
a pain-related diagnosis (all p-values < 0.001). 
Table 2. Selected characteristics (weighted %) of visits in which pain medications were 
prescribed, 2006-2015 NAMCS and NHAMCS. 
  NAMCS  NHAMCS 

















n (row %) 
P-
value† 
Sample size        
 Unweighted sample 390,538 66,987   305,570 134,953  





    
130,155,3
21 
58,568,338   
Age         
 <19 18.9 9.6 
<0.001 
 24.1 40.0 
<0.001 
 19-44 24.1 17.3  39.0 51.9 
 45-64 29.7 21.8  21.7 47.8 
 ≥65 27.3 18.1  15.2 31.1 
Gender        
 Female 58.5 17.6 
0.045 
 54.9 43.6 
<0.001 
 Male 41.5 17.1  45.1 46.1 
Race/ethnicity        
 Non-Hispanic White 71.8 17.5 
<0.001 
 59.7 44.9 
0.001 
 Non-Hispanic Black 10.3 19.0  22.5 44.8 
 Hispanic 12.5 16.9  14.6 46.3 
 Othera) 5.3 14.1  3.2 43.3 
Primary source of payment         
 Private 53.7 15.3 
<0.001 
 32.6 47.8 
<0.001 
 Medicare 25.9 20.1  18.7 35.5 
 Medicaid 12.5 17.7  28.8 45.3 
 Other 7.9 21.6  19.9 50.0 
Physician specialty        
 Generalistsb) 56.3 18.3 
<0.001 
 - - 
- 
 Otherc) 43.7 16.3  - - 
Clinician specialty        
 MDs - - 
- 
 90.1 45.8 
<0.001 
 Otherd) - -  9.9 39.6 
Repeat of visits in the past 12 
months 
      
 
 0 visit 6.9 12.4 
<0.001 
 - - 
- 
 1-2 visits 36.4 15.7  - - 
 3-5 visits 31.2 18.3  - - 
 6+ visits 25.4 21.2  - - 
Chronic conditionse)     - - - 
      <2 68.2 14.7 
<0.001 
    
      ≥2 31.8 23.8     
Concomitant medications 
prescribed 
    - - - 
     <6 83.9 13.0 
<0.001 
    
     ≥6 16.1 37.7     
Visit diagnosis        




Other pain-relatedg) 5.0 43.8  13.0 60.6 
No indication 90.3 16.1   86.5 42.7 
Note: † compares proportion differences by any pain prescription using a weight-corrected, Bonferroni-adjusted chi-squared 
statistic. a) includes Asians, American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders (NHOPI), or 
2+ reported racial/ethnic groups; b) includes general/family practice, internal medicine, pediatrics, and obstetrics and 
gynecology; c) includes psychiatry, general surgery, orthopedic surgery, cardiovascular diseases, dermatology, urology, 
neurology, ophthalmology, otolaryngology, and others; d) includes physician assistants (PAs) and nurse practitioners (NPs); e) 
was based 14 chronic conditions (yes/no) collected by the NAMCS (e.g., arthritis, congestive heart failure, and diabetes); f) was 
based on ICD-9-CM diagnostic codes 140-239, 338.3X; and g) was based on ICD-9-CM codes 338.XX, 350.1X-350.2X, 354.4X, 
355.71, 379.91. 388.7X, 719.4X, 724.1X-724.2X, 729.1X, 780.96, 786.5X, 789.XX. 
 
National prescribing trends of opioids and other pain medications 
The proportion of all outpatient visits in which any pain medication was prescribed 
increased significantly from 15.0% in 2006-2007 to 20.5% in 2014-2015 (p<0.001). Among ED 
visits, the proportion did not change significantly, ranging from 44.2% in 2006-2007 to 44.5% in 
2014-2015 (p=0.72) (Table 3).  
Non-opioid pain medication prescription increased in both settings, from 9.2% to 12.6% 
(p<0.001) in the outpatient setting and from 26.3% to 29.2% (p=0.001) in the ED setting in 




Table 3. Pain medication prescribing trends, 2006-2015 NAMCS and NHAMCS. 
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Note: †codeine, meperidine, methadone, alfentanil, hydromorphone, morphine, oxycodone, pentazocine, propoxyphene, 
sufentanil, opium, levorphanol, oxymorphone, butorphanol, nalbuphine, buprenorphine, hydrocodone, dihydrocodeine, 
remifentanil, tapentadol, and their combined products; ‡includes gabapentin and pregabalin for non-analgesics, and NSAIDs 
include acetaminophen, aspirin, diclofenac, ibuprofen, indomethacin, ketoprofen, ketorolac,naproxen, phenylbutazone, 
piroxicam, tolmetin, and tramadol. 
 
 
Factors of prescribing any pain medication 
There were several patient factors predictive of higher rates of prescribing of any pain 
medication among both outpatient and ED visits (Table 4). Among outpatient visits, pain 
medication prescription was highest among visits by patients aged 45-64 years, increasing 
significantly over time to 25.6% in 2014-2015 (p<0.001), and among visits by patients with 
Medicare, increasing significantly over time to 24.2% in 2014-2015 (p<0.001). In contrast, 
among ED visits, pain medication prescription was lowest among visits by patients with 
Medicare insurance, but increased significantly over time to 36.4% in 2014-2015 (p=0.003). 
Table 4. Stratified analysis of pain medication prescribing trends by key patient and visit 
characteristics, 2006-2015 NAMCS and NHAMCS. 



















Visit diagnosis        
 Cancer-related* 11.9% 14.3% 16.0% 15.2% 16.4%  0.037 
 Other pain-related† 43.4% 43.6% 43.3% 44.2% 44.1%  0.846 
 No indication 13.9% 15.1% 16.0% 16.5% 19.1%  <0.001 
Physician specialty        
 Generalist‡ 16.3% 17.7% 17.8% 18.4% 21.6%  <0.001 
 Other§ 13.1% 14.4% 16.8% 17.6% 19.2%  <0.001 
Age         
 <19 9.4% 10.1% 10.1% 8.4% 10.0%  0.504 




45-64 18.8% 20.3% 21.7% 22.5% 25.6%  <0.001 
≥65 14.6% 17.0% 18.2% 19.0% 21.4%  <0.001 
Gender        
 Female 15.0% 16.9% 17.6% 18.1% 20.6%  <0.001 
 Male 14.9% 15.5% 17.1% 18.0% 20.2%  <0.001 
Race/ethnicity        
 Non-Hispanic White 15.1% 16.7% 17.5% 17.9% 20.8%  <0.001 
 Non-Hispanic Black 15.6% 16.7% 19.8% 19.6% 22.9%  <0.001 
 Hispanic 14.5% 15.1% 16.6% 18.9% 19.5%  0.003 
 Other|| 13.4% 14.1% 12.7% 15.0% 15.3%  0.331 
Primary source of 
payment  
    
  
 
 Private 13.5% 14.8% 15.2% 15.7% 17.8%  <0.001 
 Medicare 15.8% 19.1% 19.8% 20.9% 24.2%  <0.001 
 Medicaid 16.6% 15.9% 19.0% 17.3% 19.5%  0.055 
 Other 19.1% 19.5% 22.6% 23.9% 22.8%  0.168 
NHAMCS 
Visit diagnosis        
 Cancer-related* 41.0% 46.2% 46.8% 47.8% 49.3%  0.074 
 Other pain-related† 57.9% 62.2% 63.2% 60.0% 59.3%  0.262 
 No indication 42.5% 43.3% 44.3% 41.3% 41.9%  0.548 
Clinician specialty        
 MDs 45.4% 46.8% 47.5% 44.7% 44.8%  0.580 
 Other¶ 35.5% 36.5% 43.5% 37.7% 42.5%  <0.001 
Age         
 <19 39.6% 41.9% 41.2% 39.0% 38.2%  0.350 
 19-44 51.4% 52.9% 54.2% 50.0% 51.1%  0.785 
 45-64 45.5% 47.5% 49.9% 47.4% 48.6%  0.024 
 ≥65 30.1% 30.1% 31.9% 31.1% 32.1%  0.118 
Gender        
 Female 45.2% 46.7% 48.0% 44.9% 45.8%  0.570 
 Male 42.9% 44.2% 45.4% 42.6% 42.9%  0.955 
Race/ethnicity        
 Non-Hispanic White 44.6% 45.3% 46.5% 43.6% 44.2%  0.646 
 Non-Hispanic Black 43.1% 46.1% 46.8% 43.7% 44.1%  0.561 
 Hispanic 44.2% 46.4% 48.5% 45.8% 46.2%  0.157 
 Other|| 42.4% 43.5% 45.6% 40.3% 44.6%  0.395 
Primary source of 
payment  
    
  
 
 Private 48.2% 48.2% 49.5% 46.1% 46.8%  0.253 
 Medicare 32.6% 35.1% 37.0% 35.3% 36.4%  0.003 
 Medicaid 43.0% 46.8% 46.7% 44.7% 45.3%  0.067 
  Other 48.5% 51.0% 52.1% 49.3% 48.3%   0.839 
Note: *was based on ICD-9-CM diagnostic codes 140-239, 338.3X; †was based on ICD-9-CM codes 338.XX, 350.1X-350.2X, 
354.4X, 355.71, 379.91, 388.7X, 719.4X, 724.1X-724.2X, 729.1X, 780.96, 786.5X, 789.XX; ‡includes general/family practice, 
internal medicine, pediatrics, and obstetrics and gynecology; §includes psychiatry, general surgery, orthopedic surgery, 
cardiovascular diseases, dermatology, urology, neurology, ophthalmology, otolaryngology, and others; ||includes Asians, 
American Indian/Alaska Natives (AIANs), Native Hawaiian or Other Pacific Islanders (NHOPI), or 2+ reported racial/ethnic 




4. STUDY 2 – METHODS AND RESULTS  
4.1 Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013-
2017 
Data Source 
We used 2013, 2015, and 2017 Medicare Prescription Drug Formulary Files, which 
include data on all Medicare Advantage and Stand-alone Part D formularies. This data was 
gathered from the CMS Prescription Drug Plan Formulary and Pharmacy Network Files. The 
following variables for each plan were collected for each opioid potentiator: coverage, prior 
authorization, specialty tier, quantity limit amount, and step therapy. 
Drug Sample 
We identified all benzodiazepines, non-benzodiazepine sedative-hypnotics, and 
gabapentinoids available in oral formulations. Benzodiazepines studied included alprazolam, 
chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, 
oxazepam, quazepam, temazepam, and triazolam. Non-benzodiazepine sedative-hypnotics 
included doxepin, zaleplon, zolpidem. Gapapentinoids included gabapentin, gabapentin 
enacarbil, and pregabalin. 
We characterized median formulary coverage of the lowest dose of the generic version of 
each drug, or the brand-name version when generics were unavailable. We focused on generics 
since they are used more commonly than the bioequivalent brand-name version, and on the 
lowest dose because higher doses can be created from lower doses. We excluded two brand-
name drugs (Rozerem and Lunesta) that became available as a generic between 2013 and 2017, 




For each drug in each year, we determined the proportion of formularies not providing 
coverage; providing restrictive coverage using one or more utilization management strategy 
(quantity limit, prior authorization, or step therapy); or providing unrestrictive coverage (no 
utilization management). We summarized median coverage across all drugs in all three years. 
Analyses were conducted in R Studio version 3.2.3.  
4.2 Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013-
2017 
Formulary Restrictions on Opioid Potentiators 
There were 12 benzodiazepines, 3 non-benzodiazepine sedative-hypnotics and 3 
gabapentinoids eligible for study. The median proportion of formularies not providing coverage 
across all drugs was 21.8% (interquartile range [IQR], 0.3-64.8%) in 2013, 14.4% (IQR, 0.0-
66.3%) in 2015, and 17.6% (IQR, 0.0-68.7%) in 2017 (Table 5). The median proportion of 
formularies providing restrictive coverage was 63.3% (IQR, 49.6-69.4%) in 2013, 70.1% (IQR, 
65.8-81.2%) in 2015, and 66.8% (IQR, 54.4-77.9%) in 2017, with the largest growth in use of 
quantity limits, a smaller increase in prior authorization, and infrequent use of step therapy. The 
median proportion of formularies providing unrestrictive coverage in the 3 years was 33.3% 
(IQR, 27.1-43.7%), 27.0% (IQR, 16.3-32.2%), and 27.9% (IQR, 18.0-41.6%), respectively. In 
2017, 47.9% of formularies provided unrestrictive coverage of at least 1 benzodiazepine, 39.9% 
of at least 1 non-benzodiazepine sedative-hypnotic, and 67.2% of at least 1 gabapentinoid. 
Table 5. Median Medicare Prescription Drug Plan Formulary Coverage and Use of Utilization Management 
Strategies for Benzodiazepines, Non-benzodiazepine Sedative-hypnotics, and Gabapentinoidsa, 2013-2017 
  Median Formulary Coverage (Interquartile Range), % 
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2013 formularies 
(n=314) 




    
No coverage 21.8 (0.3-64.8) 14.4 (0.0-66.3) 17.6 (0.0– 68.7) 
Restrictive coverage 63.3 (49.6-69.4) 70.1 (65.8-81.2) 66.8 (54.4-77.9) 




16.4 (11.8-23.5) 31.9 (17.2-38.8) 21.0 (14.0-39.0) 
 Requires step therapy 0 (0-0) 0.0 (0.0-2.7) 0 (0-0.8) 
Coverage with no restrictions 33.3 (27.1-43.7) 27.0 (16.3-32.2) 27.9 (18.0– 41.6) 
a12 benzodiazepines, 3 non-benzodiazepine sedative-hypnotics, and 3 gabapentinoids were included 
 
Medicare Coverage of Individual Opioid Potentiators 
Medicare coverage in 2017 of each drug varied (Table 6). Quazepam and gabapentin 
enacarbil were not covered by any plan. Lorazepam, diazepam, clonazepam, doxepin, 
pregabalin, and gabapentin were covered by all. Among benzodiazepines, hypnotics (estazolam, 
flurazepam and triazolam) had lower rates of coverage, whereas anxiolytics (alprazolam, 
diazepam, and lorazepam) had higher rates, albeit usually with restrictions. 
Table 6. Medicare Prescription Drug Plan Formulary Coverage and Use of Utilization Management for 























Benzodiazepines       
Alprazolam 11.9  21.9  67.1 75.7  7.5  0  
Chlordiazepoxide 48.9 37.6  13.5 57.4  17.7 0  
Clonazepam 0  28.8  71.2 62.2  22.5  2.1  
Clorazepate 0  27.2  72.8 63.8  37.0  0  
Diazepam 0 19.6  80.4 72.0  39.7  0  
Estazolam 59.4  33.6  7.0 55.9  23.4  0  
Flurazepam 56.9  38.2  4.9 45.2  17.9  0  
Lorazepam 0  17.5  82.5 74.6  19.6 0  
Oxazepam 33.9  28.6 37.5 34.6  28.3  0  
Quazepamb 100       
Temazepam 45.2  22.8  32.0 63.8  58.5  0 









Doxepin 0  39.4  60.6 0  57.1  3.4  
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a Restrictive coverage defined as use of one or more utilization management strategy: quantity limit, prior 
authorization requirement, and step therapy requirement.b Drug was not covered by any formulary over the study 
period 
 
5. STUDY 3 – METHODS AND RESULTS  
5.1 Medicare Formulary Coverage of Brand-Name Drugs with Available FDA-Approved 
Therapeutically Interchangeable Generics 
Data Source 
We used June 2016 CMS Prescription Drug Plan Formulary Files, inclusive of 374 
Medicare Advantage and stand-alone Part D formularies. This data was gathered from the CMS 
Prescription Drug Plan Formulary and Pharmacy Network Files. The following variables for 
each plan were collected for each brand-name drug: coverage, prior authorization, specialty tier, 
quantity limit amount, and step therapy. 
Drug Sample 
We included the top 100 non-biologic drugs as measured by total retail sales in 2016 35. 
We included all brand-name drugs without an FDA-approved bioequivalent generic as of June 
2016, but with at least one therapeutically interchangeable generic. Regulatory data, including 
status of generic approval, for all of the brand-name drugs were collected from the Drug@FDA 
database. For this study, therapeutically interchangeable generics were determined using the U.S. 
Pharmacopeia Medicare Model Guidelines or based on prior studies 33, 36. 
Zaleplon 23.3  3.8  72.9 78.6  54.8  10.0  
Zolpidem 4.5 1.4  94.1 84.5  65.4  8.3  
Gabapentinoids          
Gabapentin 0  59.8  40.2 40.2  0  0  
Gabapentin 
enacarbilb 








For each brand-name drug and their corresponding therapeutically interchangeable 
generic(s), we compared tier placement and utilization management. Tier placement broadly 
determines beneficiary out-of-pocket costs, the lowest of which are for drugs in tier 1 and 6; tier 
1 generally includes preferred medications and tier 6, when present, includes “select-care” 
generics. Utilization management encompasses three separate strategies to limit prescribing: step 
therapy, prior authorization and quantity limits, which were used to calculate a restrictiveness 
score based on the number of strategies used. For both estimates, for each formulary, the brand-
name drug was compared to the therapeutically interchangeable generic available at the lowest 
tier or with the least restrictive utilization management; this information was used to calculate 
percentages across all covering formularies, which were summarized as medians for all drugs 
that met our study’s inclusion criteria. All statistical analyses were performed using R Studio 
version 3.2.5.  
5.2 Medicare Formulary Coverage of Brand-Name Drugs with Available FDA-Approved 
Therapeutically Interchangeable Generics 
Results as described in the following sections are shown in Table 7. 
Coverage of Drug Sample 
There were 24 brand-name drugs that met the inclusion criteria, for which there was a median of 
3.0 (range: 1-9) therapeutically interchangeable generic drugs. At least one Medicare formulary 
covered both the brand-name and corresponding therapeutically interchangeable generic for 23 
drugs (95.8%; ranolazine was not covered by any formulary), although the median proportion of 
formularies providing no brand-name drug coverage was 42.4% (IQR, 2.5-71.5).  
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Examining Tiering of Brand-Name versus Therapeutic Interchangeables 
The median proportion of formularies that placed therapeutically interchangeable generics in a 
lower tier than the corresponding brand-name drug was 86.0% (IQR, 85.5-90.3). For 17 of 23 
(73.9%) brand-name drugs, more than 10% of formularies placed the brand-name and 
therapeutically interchangeable generic on the same tier. 
Formulary Restrictions on Brand-Name versus Therapeutic Interchangeables 
For 10 (43.5%) brand-name drugs, 50% or more of formularies did not use any utilization 
management restrictions, whereas for 14 (60.9%), more than 10% of formularies had equivalent 
utilization management restrictiveness scores for brand-name and their corresponding 
therapeutically interchangeable drugs. 
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Table 7. Medicare Prescription Drug Plan Formulary Coverage of the Top 100 Brand-Name Drugs in 2016 without a Bioequivalent 
Generic but with a Therapeutically Interchangeable Generic, including Tier Placement and Utilization Management. 
 

















Strategies Applied to 
Brand 
Strategies Not 





















Pitavastatin 66.3 92.1 7.9 0 37.3 23.8 0 38.9 0 









Apixaban 22.5 85.5 14.5 0 51.4 0 0 48.6 0 
Dabigatran 1.9 85.8 14.2 0 53.1 0 0 46.9 0 
Edoxaban 81.3 95.7 4.3 0 42.9 0 0 57.1 0 







Prasugrel 13.6 88.5 11.5 0 15.8 24.8 0 58.4 1.0 





Carvedilol CRf 70.6 94.5 5.5 0 41.8 0 0 58.2 0 






Azilsartan 74.3 92.7 7.3 0 33.3 10.4 0 56.3 0 
Olmesartan 47.6 92.9 7.1 0 26.0 16.9 0 56.6 0.5 
Anti-
anginal 
Ranolazinei 100         
Gabapentin
oid 
Pregabalinj 0 85.8 14.2 0 42.8 29.7 0 19.7 7.8 
SGLT-2 
inhibitor 
Dapagliflozink 55.6 85.5 13.3 1.2 33.7 57.2 0 8.4 0.7 
Stimulant 
Lisdexamfetamine
l 76.5 87.5 12.5 0 15.9 40.9 0 35.2 8.0 
Anti-
psychotic Lurasidone
m 0 85.8 14.2 0 67.3 23.3 0 9.4 0 
Smoking 
cessation Varenicline
n 0 83.7 16.0 0.3 59.3 9.1 0 23.3 8.3 
PDE-5 
inhibitor 









Cinacalcetq 0 56.7 18.7 24.6 22.2 22.2 7.5 28.6 19.5 
Immuno-
modulatory 
Teriflunomider 43.9 78.1 17.6 4.3 87.1 11.5 0 0.8 0.6 
Amino-
salicylate 
Mesalamines 40.9 86.4 13.6 0 26.2 0 0 73.8 0 






















a Generic refers to therapeutically interchangeable generic equivalent 
b Therapeutically interchangeable generic drugs for pitavastatin and rosuvastatin were atorvastatin, simvastatin, lovastatin, pravastatin, fluvastatin 
c Therapeutically interchangeable generic drugs for dalteparin were enoxaparin and fondaparinux 
d Therapeutically interchangeable generic drug for direct oral anti-coagulants (apixaban, dabigatran, edoxaban and rivaroxaban) was warfarin 
e Therapeutically interchangeable generic drug for prasugrel and ticagrelor was clopidogrel 
f  Therapeutically interchangeable generic drugs for carvedilol CR were atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol succinate, nadolol, 
propanalol 
g Therapeutically interchangeable generic drugs for nebivolol were atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol succinate, metoprolol tartrate, 
nadolol, propanalol 
h Therapeutically interchangeable generic drugs for azilsartan and olmesartan were valsartan, candesartan, eprosartan, irbesartan, losartan, telmisartan 
I Therapeutically interchangeable generic drugs for ranolazine were isosorbide dinitrate, isosorbide mononitrate, amlodipine, nicardipine, nifedipine, felodipine 
j Therapeutically interchangeable generic drug for pregabalin was gabapentin 
k Therapeutically interchangeable generic drugs for sodium-glucose co-transporter 2 (SLGT2) inhibitor dapagliflozin were glipizide, glyburide, glimepiride 
l Therapeutically interchangeable generic drugs for lisdexamfetamine were methylphenidate, dextroamphetamine 
m Therapeutically interchangeable generic drugs for lurasidone were aripiprazole, olanzapine, quetiapine, ziprasidone, risperidone, clozapine 
n Therapeutically interchangeable generic drug for varenicline was bupropion 
o Therapeutically interchangeable generic drugs for phosphodiesterase-5 (PDE-5) inhibitor tadalafil were sildenafil, vardenafil 
p Therapeutically interchangeable generic drugs for mirabegron were oxybutynin, tolterodine, darifenacin 
q Therapeutically interchangeable generic drug for cinaclcet was paricalcitol 
r Therapeutically interchangeable generic drug for teriflunomide was leflunomide 
s Therapeutically interchangeable generic drug for mesalamine was sulfasalazine 
h Utilization management strategies include: 1) step therapy, which requires using a lower-cost drug before  a more expensive drug can be used, 2) prior 
authorization, which requires that a prescription medication meet specific criteria before it can be approved by the health plan for coverage, and 3) quantity 






6.1 Study Findings and Context 
This study provides both a focused and systematic overview of the relationship between 
CMS formulary regulations and evidence-based, cost-effective prescribing through three 
analyses. The first study was an examination of national opioid versus non-opioid analgesic 
prescription rates before and after release of CDC guidelines encouraging prescription of non-
opioid analgesics, and the second was a characterization of CMS formulary coverage, including 
utilization management strategies, of opioid potentiators such as benzodiazepines, non-
benzodiazepine sedative hypnotics and gabapentinoids in light of increasing morbidity from co-
prescription of opioids and opioid potentiators. Finally, the third study examined how 2016 
Medicare prescription drug plan formularies incentivize selection of top 100-grossing brand-
name drugs without bioequivalent generics compared to their corresponding therapeutically 
interchangeable generic drugs through tier placement and utilization management strategies, in 
anticipation of the 2020 CMS proposal for an indication-based formulary. 
6.2 Impact of 2013 CMS Cautionary Opioid Guidelines on Rate of Opioid Prescription 
In this study of pain medication prescribing in a nationally representative sample of 
outpatient and ED visits from 2006-2015, overall rates of pain medication prescribing were high, 
with a prescription provided among approximately one in five outpatient visits and nearly one in 
two ED visits. Over this period, we found increased opioid pain medication prescribing in the 
outpatient setting, rising to nearly one in twelve visits. Finally, reassuringly, there was an 
increase in non-opioid pain medication prescribing in both the outpatient and ED settings, an 
area that has not been previously reported or well-investigated.  
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The prescription of opioids increased in the outpatient setting. Chronic non-cancer-
related pain is a common presentation in primary care, and the difficulties of determining when 
to prescribe opioids, and for how long, has been acknowledged in multiple studies 37, 38. In 
primary care, there have been numerous efforts to encourage appropriate opioid prescribing, 
including targeted physician education 39. Requiring patients to have a structured care system 
comprising of periodic visits dedicated to monitoring and discussion of their current opioid 
medications has been shown to reduce opioid prescriptions 40. Ongoing education for patients 
who are currently struggling with opioid dependence is especially important, as patients who 
have experienced a non-fatal overdose are at high risk of fatal opioid overdose throughout this 
period 41.  A multicomponent system involving a nurse care manager, electronic registry, data-
driven academic detailing (face-to-face education of prescribers by trained health care 
professionals in order to improve evidence-based prescribing of targeted drugs), and clinical 
decision support (such as care reminders, up-to-date guidelines, recommendations, and databases 
that can provide information relevant to particular patients)  has been shown to improve 
adherence to opioid-prescribing guidelines 42, 43. Nonetheless, our results show that there was a 
steady increase in opioid prescribing across the ten years period, suggesting the need for 
implementing effective interventions such as those described above, and developing still others, 
that attempt to reduce opioid prescribing for chronic pain in the primary care setting. 
The increase in non-opioid pain medication prescribing in both outpatient and emergency 
room settings is reassuring. Many reports have linked increased opioid prescribing to increased 
opioid-related deaths 17, 44. Previous reports on pain medication, specifically in the ED, reported 
an increase in opioid prescribing and no change in non-opioid prescribing from 2001-2010 45. 
Our results showed the opposite, with an increase in non-opioid prescription. Our results 
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suggests a response by ED providers to replace opioid treatments with non-opioid NSAIDs for 
patients presenting with pain disorder starting in 2010 16. Likewise, multiple studies in the 
primary care setting have shown the benefit of choosing non-opioid therapies for chronic pain. 
Our results show that outpatient physicians are starting to use evidence-based guidelines for 
managing chronic pain 46, 47.  
6.3 Opioid Potentiators: Are Formulary Regulations Being Used to Control Unsafe 
Prescribing? 
From 2013-2017, Medicare prescription drug plan formularies had relatively unchanged 
rates of benzodiazepine, non-benzodiazepine sedative-hypnotic, and gabapentinoid coverage 
with small increases in use of quantity limits. More than a quarter of formularies provided 
unrestrictive coverage of these potentially unsafe opioid potentiators in 2017, and approximately 
20% of formularies provided unrestrictive coverage of alprazolam and lorazepam, the two most 
commonly prescribed benzodiazepines. Furthermore, despite concern about the potential for 
prescription abuse, gabapentin was covered without restrictions by almost 60% of formularies.  
As CMS formulary coverage is a representation of national prescribing patterns, this 
study suggests that utilization management strategies are being sub-optimally implemented to 
restrict prescribing of opioid potentiators, similar to prescribing of opioids themselves as 
reported in the paper by Samuels et al.18 The CMS overutilization monitoring system currently 
flags co-prescription of benzodiazepines and opioids, and CMS has proposed flagging co-
prescription of other potentiator drugs with opioids.19 Although we could not examine co-
restriction of opioids and opioid potentiators using Medicare formulary data, our findings 
suggest opportunity for greater use of utilization management strategies to reduce use of these 
potentially unsafe medications. 
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6.4 Treatment of Therapeutic Equivalents by CMS Formularies 
In 2016, more than 85% of Medicare prescription drug plan formularies incentivized use 
of therapeutically interchangeable generic drugs over brand-name drugs through tier placement 
and utilization management. However, a substantial portion of formularies (80%) provided 
similarly restrictive coverage of some brand-name drugs and their therapeutically 
interchangeable generics, including the same tier placement or utilization management, thereby 
missing opportunities to incentivize prescribing of less costly generics. Furthermore, in 52% of 
the drug study sample, there were multiple formularies that used more restrictive utilization 
management strategies on therapeutic equivalents compared to branded drugs. While our study 
focused on therapeutically interchangeable generic drug coverage, our findings align with a 
study showing that while most 2016 Part D formularies incentivized bioequivalent generic drugs, 
there were formularies offering more favorable placement for brand-name drugs 48.  
Our findings can inform the proposed 2020 indication-based formulary design, 
suggesting that restricted coverage of brand-name drugs and favored coverage of their 
therapeutically interchangeable generics might further incentivize use of generic drugs and 
potentially reduce both Medicare and beneficiary spending. 
6.5 Implications of Findings 
Restricting formulary coverage for prescription drugs is a strategy to increase safe and 
cost-effective prescribing for a large portion of the US patient population. Using opioids as a 
case study, our initial findings showed that opioid prescription has increased in the outpatient 
setting even in light of 2013 CDC guidelines encouraging prescription of non-opioid analgesics. 
These results correlate with the Samuels et al. paper noting unrestricted formulary coverage of 
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high-dose opioids 18, suggesting that formulary restrictions may be a good measure with which to 
monitor prescription practices of potentially unsafe drugs. Our findings concerning unrestricted 
coverage of multiple opioid potentiators suggests that while CMS utilization management 
strategies are in place, they are being underutilized, leading to a concern that the restriction 
strategies alone are not promoting safe prescribing. In this case, it may be time to further 
strengthen the CMS overutilization system by adding a new measure that monitors concurrent 
opioid and opioid potentiator use and limits the supply of both medications for the first 
prescription filled for acute pain 49. 
  The final study examined how formularies incentivize prescribing of therapeutic 
interchangeable generics over their corresponding high-grossing brand-name drugs across a 
breadth of therapeutic areas. The findings are concerning in that favorable or even equal 
formulary placement of branded drugs compared to therapeutically interchangeable generics 
incentivizes use of more expensive brand-name products and can lead to higher out-of-pocket 
costs for Medicare beneficiaries and higher expenditures for the Part D program.  
6.6 Implications for Future Formulary Regulation and Structure 
Perhaps the most direct and straightforward option to encourage safe and cost-effective 
prescribing is for Medicare to prohibit giving branded products or certain classes of drugs more 
favorable formulary placement than generic products or preferred alternative classes. This has 
been suggested in previous work 31– however, it may limit choices in cases where the branded 
drug has a differential effect or cases where the benefit of a potentially harmful class of drugs 
outweighs the potentially harmful side effects. Furthermore, treatment of generic drugs versus 
branded drugs in the CMS formulary is complicated by the policy of volume-based rebates. 
Currently, prescription drug plans earn some of their profits through rebates and other price 
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concessions paid by pharmaceutical manufacturers in exchange for inclusion on certain tiers of 
the formulary 50. As a result, generic drugs are often placed in a higher tier or treated more 
restrictively, if not left off of the formulary entirely. Thus, it might be necessary to also change 
the incentive structure of Part D plans. 
Another solution is on the horizon in the form of a proposed indication-based formulary 
for all participating CMS prescription drug plans. This would by definition limit use of brand-
name drugs to only certain indications, leaving much more opportunity for providers to utilize 
therapeutically interchangeable generics, especially in the relatively common occurrence of there 
being no bioequivalent generic available. Unfortunately, the issue of generic drug substitution is 
complex and often poorly understood by physicians, even where bioequivalents are concerned 51, 
52. Therapeutically interchangeable generics are even more contentious, as direct evidence to 
support equivalence is often lacking and FDA regulatory guidelines are somewhat ambiguous 53, 
54. Further work to establish guidelines for therapeutic exchange across multiple therapeutic 
areas will be necessary in order for the proposed formulary structural changes to have 
meaningful impact. 
7. LIMITATIONS 
There are important limitations to consider in this study. For the first analysis, both 
NAMCS and NHAMCS limit the number of medications that are listed as prescribed during each 
visit. For patient visits where more than eight medications were prescribed, fentanyl or other 
opioid prescriptions, and especially NSAIDs (which are not consistently prescribed as they are 
available over the counter), may have not been captured, potentially underestimating pain 
medication prescribing. Second, NHAMCS only captures ED visits and does not include visits to 
hospital-based outpatient clinics, which limits the generalizability of our findings. Third, 
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NAMCS and NHAMCS are representative of a nationwide physician sample but likely 
underestimate physician prescriptions. Of note, change in clinical practice often occurs more 
slowly and the CDC guidelines release in 2013 may not have been dispersed and implemented 
fully in our research sample that runs from 2006-2015. 
For the second analysis, we were unable to examine co-restriction of opioids and opioid 
potentiators using Medicare formulary data. Finally for the third analysis using CMS formulary 
data, Medicare prescription drug formulary data are not linked to beneficiary spending data, 
limiting our understanding of the actual patient out-of-pocket costs of brand-name and 
therapeutically interchangeable generic drugs.  
 
8. CONCLUSION 
Controlling the cost of prescription drugs is integral to improving both patient access and 
adherence to treatment. The Center for Medicare & Medicaid Services (CMS) formularies, 
which cover around 17% of the US population, have uniformly adopted utilization management 
strategies, such as quantity limits, prior authorization, and step therapy, in order to promote safe, 
evidence-based and cost-effective prescribing. These strategies are in place to impact drug 
prescription rates as well as to incentivize use of biological or therapeutically interchangeable 
generics over brand-name drugs. Thus far, the implementation of utilization management 
strategies for commonly prescribed drugs has not been thoroughly studied.  
This study presents three main analyses. The first showed that there has been an increase 
in outpatient opioid prescribing that correlates with the lack of formulary restriction of high-dose 
opioids shown previously. Our second study reported a similar lack of formulary restriction for 
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opioid potentiators such as benzodiazepines, non-benzodiazepine sedative-hypnotics and 
gabapentinoids. Finally, our third study showed that therapeutically interchangeable generics are 
not less restricted than their corresponding brand-name drugs across formularies. Overall, while 
formulary restrictions are in place, they are often underutilized in promoting safe and cost-
effective prescribing. 
The results of this comprehensive study on safe and cost-effective drug prescription 
strategies suggest that these strategies alone may not be sufficient to reduce over-prescription of 
potentially unsafe drugs like opioid potentiators, or to incentivize prescription of cost-saving 
generics over brand-name drugs. The CMS overutilization monitoring system should be updated 
to not only monitor, but also actively restrict prescription of potentially harmful drugs or drug 
combinations. The Center for Medicare & Medicaid Services (CMS) has proposed an indication-
based formulary design starting in 2020, allowing Medicare Advantage and Part D prescription 
drug plans to cover drugs only for select indications, which could increase formulary negotiating 
power and secure more competitive pricing. With these changes, CMS can ensure continued 
patient access to affordable and safe prescription drugs. 
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